about
First-in-Human Assessment of the Novel PDE2A PET Radiotracer 18F-PF-05270430.The Safety and Efficacy of PF-04958242 in Age-Related Sensorineural Hearing Loss: A Randomized Clinical Trial.Impact of BPRS interview length on ratings reliability in a schizophrenia trial.Attenuation of ketamine-induced impairment in verbal learning and memory in healthy volunteers by the AMPA receptor potentiator PF-04958242.Phosphodiesterase 10A Inhibitor Monotherapy Is Not an Effective Treatment of Acute SchizophreniaA novel approach to evaluate the pharmacodynamics of a selective dopamine D1/D5 receptor partial agonist (PF-06412562) in patients with stable schizophreniaA Proof-of-Concept Study Evaluating the Phosphodiesterase 10A Inhibitor PF-02545920 in the Adjunctive Treatment of Suboptimally Controlled Symptoms of SchizophreniaActivation of D1 receptors affects human reactivity and flexibility to valued cues
P50
Q37390678-BC217796-E038-4C2A-8F82-B8BE517CF7AEQ38411202-1AEB216C-AC22-42E1-8D32-FECBB58BBE44Q38418308-06EE5723-819B-42B9-8497-58498DE8DB0FQ47789718-9E57F9FA-AA2F-4553-92D1-11742CEA4AE9Q91119333-F0D292CC-C0FC-402F-B7E1-2C947D834871Q91542201-2DEAF7BF-A5AB-4F03-95C3-5E8A6119E5B7Q92792088-3149A5E0-147D-4BF5-AA4E-EB4BF1D83B0FQ92805569-3D87278E-FC5F-4585-95CA-A427FF3DD8DD
P50
description
investigador
@es
researcher
@en
name
Nicolas DeMartinis
@en
type
label
Nicolas DeMartinis
@en
prefLabel
Nicolas DeMartinis
@en
P31
P496
0000-0003-4075-1397